-$0.58 EPS Expected for Arcturus Therapeutics Ltd (NASDAQ:ARCT) This Quarter

Equities analysts expect Arcturus Therapeutics Ltd (NASDAQ:ARCT) to post ($0.58) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Arcturus Therapeutics’ earnings, with estimates ranging from ($0.63) to ($0.52). Arcturus Therapeutics posted earnings per share of ($0.50) during the same quarter last year, which suggests a negative year-over-year growth rate of 16%. The company is expected to announce its next quarterly earnings report on Monday, October 7th.

On average, analysts expect that Arcturus Therapeutics will report full year earnings of ($2.32) per share for the current financial year, with EPS estimates ranging from ($2.54) to ($2.02). For the next year, analysts forecast that the company will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.41) to ($1.43). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Arcturus Therapeutics.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.15). The company had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $3.47 million. Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%.



Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a research report on Tuesday, April 16th. ValuEngine lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, June 17th. Chardan Capital set a $18.00 price objective on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. Finally, HC Wainwright assumed coverage on shares of Arcturus Therapeutics in a research report on Friday, April 5th. They set a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Arcturus Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.83.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $416,000. Nikko Asset Management Americas Inc. acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $438,000. Finally, ARK Investment Management LLC grew its position in shares of Arcturus Therapeutics by 13.7% in the 1st quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after purchasing an additional 111,968 shares during the period. 13.58% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ ARCT traded up $0.10 during mid-day trading on Tuesday, reaching $9.89. The company had a trading volume of 2,056 shares, compared to its average volume of 75,483. The business has a fifty day simple moving average of $6.85. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 2.43. The stock has a market capitalization of $104.82 million, a P/E ratio of -4.63 and a beta of 2.10. Arcturus Therapeutics has a 12-month low of $4.11 and a 12-month high of $10.29.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Further Reading: Price-Sales Ratio

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.